Skip to content

Clinical trials

Recruiting Attention Deficit Disorder with Hyperactivity trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Attention Deficit Disorder with Hyperactivity Status: Recruiting Country / region: United States Clear all

73 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20081
20141
20163
20171
20182
20191
20202
20211
20226
20234
202413
202519
202619

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Recruiting73

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
National Institute of Mental Health (NIMH)5
Children's Hospital Medical Center, Cincinnati4
Massachusetts General Hospital3
Axsome Therapeutics, Inc.2
Duke University2
Florida State University2
Francisco Gonzalez-Lima, PhD2
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.2
Icahn School of Medicine at Mount Sinai2
Milton S. Hershey Medical Center2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Attention Deficit Disorder with Hyperactivity73
Autistic Disorder5
Autism Spectrum Disorder4
Oppositional Defiant Disorder4
Stress Disorders, Post-Traumatic3
Anemia, Sickle Cell2
Anxiety Disorders2
Attention Deficit and Disruptive Behavior Disorders2
Bipolar Disorder2
Brain Injuries, Traumatic2

Trials

Showing 1 to 25 of 73. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.